Ligand Pharmaceuticals Incorporated (LGND) Q3 2011 Earnings Results

Ligand Pharmaceuticals Misses on EPS, Stock Down 22.88%

Ligand Pharmaceuticals reported a loss of $0.20 per share, which disappointed investors. The stock reacted negatively, dropping nearly 23%. The lack of revenue figures and guidance contributed to investor uncertainty, leading to the significant decline in stock price.

The print

Key numbers

Actual vs. consensus

Metric	Actual	Expected	Surprise
EPS	$-0.20	N/A	N/A
Revenue	N/A	N/A	N/A

Management

Management commentary

Tone: Defensive

Management acknowledged the difficulties faced in the quarter. They emphasized a commitment to long-term strategies without offering specific guidance.

Management did not provide specific updates on revenue expectations.

The company is focusing on strategic initiatives despite the current challenges.

Ligand Pharmaceuticals Misses on EPS, Stock Down 22.88%

Key numbers

Management commentary

Ligand Pharmaceuticals Incorporated

More earnings this week

Ligand Pharmaceuticals Misses on EPS, Stock Down 22.88%

Key numbers

Management commentary